Electrical Stimulation Devices Market Report 2025

The electrical stimulation devices market size has grown strongly in recent years. It will grow from $7.75 billion in 2024 to $8.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to sports and fitness applications, shift towards non-invasive therapies, clinical validation, rising chronic health conditions, regulatory support.

The electrical stimulation devices market size is expected to see strong growth in the next few years. It will grow to $12.33 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to aging population trends, rising incidence of chronic health conditions, expanding clinical validation, supportive regulatory environment, mental health emphasis, increased focus on preventive healthcare. Major trends in the forecast period include regulatory support and reimbursement policies, rising chronic health conditions, clinical research and evidence, shift towards non-invasive therapies, increased sports and fitness applications.

The rising prevalence of muscle disorders is anticipated to drive growth in the electrical stimulation devices market. Muscle disorders comprise a range of inherited genetic conditions that lead to progressive muscle weakness over time. These disorders can result in weakness or paralysis even when the nervous system remains intact. Electrical stimulation devices are designed to alleviate muscle weakness by generating controlled and comfortable muscle contractions using skin electrodes and a portable stimulator. For instance, in June 2024, the Australian Institute of Health and Welfare, an Australian government agency, estimated that around 7.3 million Australians (29%) were living with chronic musculoskeletal conditions in 2022. Among these individuals, 4 million (16%) reported experiencing back issues, 3.7 million (15%) were diagnosed with arthritis, and 854,000 (3.4%) were affected by osteoporosis or osteopenia. Consequently, the increasing incidence of muscle disorders is driving the growth of the electrical stimulation devices market.

The rising prevalence of chronic diseases is anticipated to drive the growth of the electric stimulation device market in the coming years. Chronic diseases are long-term medical conditions that typically develop slowly and persist for more than three months, often necessitating ongoing management rather than a cure. The increase in chronic diseases can be attributed to several factors, including an aging population, sedentary lifestyles, poor dietary habits, a higher prevalence of obesity, and environmental influences. Electric stimulation devices are essential for managing chronic diseases as they help alleviate pain, improve muscle function, and enhance nerve recovery by delivering targeted electrical impulses to affected areas. For example, a report published by the World Health Organization (WHO), a Switzerland-based intergovernmental organization, indicated in February 2024 that there were approximately 20 million new cancer cases and 9.7 million deaths worldwide in 2022. Lung cancer was the most prevalent, with 2.5 million new cases (12.4%), followed by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). By 2050, new cancer cases are projected to increase by 77%, reaching over 35 million annually. Thus, the rising prevalence of chronic diseases is propelling the growth of the electric stimulation device market.

Technological advancements serve as a prominent trend gaining traction in the electrical stimulation market. Leading market entities are introducing FDA-approved, state-of-the-art electrical stimulation devices to elevate patient treatment outcomes. A case in point is Abbott Laboratories, a renowned US-based medical device company operating in the field of electrical stimulation devices. In August 2022, Abbott Laboratories unveiled Proclaim Plus, a technologically advanced spinal cord stimulation device authorized by the US FDA. This cutting-edge device, leveraging FlexBurst360 therapy, represents the next generation of BurstDR stimulation therapy. It offers a broader myotomal coverage at lower amplitudes compared to single-area stimulation, thereby delivering personalized pain relief for a diverse range of painful conditions. The introduction of such innovative and advanced therapies expands the array of available treatments, amplifying the effectiveness and options in the realm of electrical stimulation devices.

The development of innovative products such as nerve stimulators represents a strategic approach for major companies in the electrical stimulation device market to broaden their customer base, increase sales, and drive revenue growth. Nerve stimulators, medical devices that deliver controlled electrical impulses to nerves, have garnered attention due to their potential therapeutic applications. For instance, Checkpoint Surgical, a US-based medical device company, introduced Checkpoint Gemini in September 2022. This device distinguishes itself by its exceptional precision in nerve stimulation. The innovative bipolar probe design of Checkpoint Gemini enables highly accurate direct nerve stimulation, particularly at the fascicular level. Surgeons benefit from this technology as it allows for targeted energy delivery to specific areas, enhancing clarity in identifying the responsible fascicle within a nerve for a particular response. The precision offered by Checkpoint Gemini represents a significant leap forward in nerve stimulation technology, catering to the demand for more accurate and sophisticated medical devices.

In August 2022, Medtronic, a US-based medical device company, acquired Affera Inc. for an undisclosed sum. This acquisition allowed Medtronic to enhance its cardiac ablation portfolio by introducing its first cardiac mapping and navigation platform, which offers a fully integrated solution for diagnostic, focal pulsed field, and radiofrequency ablation. The acquisition includes the Affera Prism-1 cardiac mapping and navigation platform, which will be compatible with both Medtronic's and other manufacturers' therapeutic catheters and technologies. Affera Inc. is a US-based manufacturer specializing in electrical stimulation devices.

Major companies operating in the electrical stimulation devices market include Boston Scientific Corporation, Abbott Laboratories, DJO Global Inc., BTL Corporate Inc., Nevro Corp., NeuroMetrix Inc., Zynex Inc., BioMedical Life Systems, RS Medical, Biotronik Inc., CU Medical System Inc., Beijing Pins Medical Co.Ltd., MicroPort Scientific Corporation, Koninklijke Philips N.V, Bioinduction Ltd., Soterix Medical Inc., Medtronic plc, MYOLYN, Cogentix Medical Inc., Cyberonics Inc., Stimwave Technologies, EndoStim Inc., SPR Therapeutics, Nuvectra Corporation, ElectroCore Inc., Axonics Modulation Technologies Inc., Inspire Medical Systems Inc., Second Sight Medical Products Inc., Cochlear Limited.

North America was the largest region in the electrical stimulation devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the electrical stimulation devices market report during the forecast period. The regions covered in the electrical stimulation devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the electrical stimulation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Electrical stimulation devices are compact electronic devices affixed to the skin using electrodes and worn externally by patients. They are utilized for reducing acute post-operative pain and swelling, as well as for treating chronic intractable pain. These devices emit gentle electrical pulses through the skin and are effective in addressing a variety of nerve and musculoskeletal pain disorders.

The primary types of electrical stimulation devices include deep brain stimulation devices, neuromuscular electrical stimulation devices, sacral nerve stimulation devices, spinal cord stimulation devices, and others. Deep brain stimulation devices involve a medical treatment method that employs an implanted device to deliver electrical currents to specific areas of the brain. This treatment is commonly used for managing movement disorders associated with conditions such as Parkinson's disease (PD), dystonia, essential tremors, and other neurological conditions. Electrical stimulation devices are applied across various domains, including pain management, neurological and movement disorder management, musculoskeletal disorder management, metabolism, gastrointestinal management, and more. These devices are utilized by hospitals, ambulatory surgical centers, and other healthcare facilities.

The electrical stimulation devices market research report is one of a series of new reports that provides electrical stimulation devices market statistics, including electrical stimulation devices industry global market size, regional shares, competitors with an electrical stimulation devices market share, detailed electrical stimulation devices market segments, market trends and opportunities, and any further data you may need to thrive in the electrical stimulation devices industry. This electrical stimulation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The electrical stimulation devices market consists of sales of implantable electronic stimulation devices, vagus nerve stimulation (VNS) devices and transcutaneous electrical nerve stimulation (TENS) devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.